Sincalide

Sincalide

Systematic (IUPAC) name
α-aspartyl-O-sulfotyrosylmethionylglycyltryptophylmethionyl-α-aspartylphenylalaninamide
Clinical data
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Pregnancy category	US: B (No risk in non-human studies)
Legal status	US: ℞-only Available on a named-patient basis (UK)
Routes of administration	Intravenous
Identifiers
CAS Number	25126-32-3 Y
ATC code	V04CC03
PubChem	CID 32800
IUPHAR/BPS	864
ChemSpider	8009168 N
UNII	M03GIQ7Z6P N
KEGG	D05845 Y
ChEMBL	CHEMBL1121 N
Synonyms	1-De(5-oxo-L-proline)-2-de-L-glutamine- 5-L-methioninecaerulein, 3-[[2-[[2-[[2-[[2-[[2-[(2-amino-3-carboxy-propanoyl) amino]-3-(4-sulfooxyphenyl)propanoyl]amino]-4- methylsulfanyl-butanoyl]amino]acetyl]amino]-3- (1H-indol-3-yl)propanoyl]amino]-4-methylsulfanyl- butanoyl]amino]-3-[(1-carbamoyl-2-phenyl-ethyl) carbamoyl]propanoic acid
Chemical data
Formula	C49H62N10O16S3
Molar mass	1143.27 g/mol
SMILES CSCC[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)[C@H](CC(=O)O)N
InChI InChI=1S/C49H62N10O16S3/c1-76-18-16-34(55-47(69)37(58-44(66)32(50)23-41(61)62)21-28-12-14-30(15-13-28)75-78(72,73)74)45(67)53-26-40(60)54-38(22-29-25-52-33-11-7-6-10-31(29)33)48(70)56-35(17-19-77-2)46(68)59-39(24-42(63)64)49(71)57-36(43(51)65)20-27-8-4-3-5-9-27/h3-15,25,32,34-39,52H,16-24,26,50H2,1-2H3,(H2,51,65)(H,53,67)(H,54,60)(H,55,69)(H,56,70)(H,57,71)(H,58,66)(H,59,68)(H,61,62)(H,63,64)(H,72,73,74)/t32-,34-,35-,36-,37-,38-,39-/m0/s1 N Key:IZTQOLKUZKXIRV-YRVFCXMDSA-N N
NY (what is this?)  (verify)

Sincalide (INN) is a cholecystokinetic drug administered by injection to aid in diagnosing disorders of the gallbladder and pancreas. It is the 8-amino acid C-terminal fragment of cholecystokinin, and also known as CCK-8.

Common adverse effects following administration include abdominal discomfort and nausea. These effects are more pronounced following rapid infusion.

Clinical Use

Indications

Sincalide may be used to stimulate gallbladder contraction, as may be assessed by contrast agent cholecystography or ultrasonography, or to obtain by duodenal aspiration a sample of concentrated bile for analysis of cholesterol, bile salts, phospholipids, and crystals. It can also be used to stimulate pancreatic secretion (especially in conjunction with secretin) prior to obtaining a duodenal aspirate for analysis of enzyme activity, composition, and cytology. In some instances it is used to accelerate the transit of a barium meal through the small bowel, thereby decreasing the time and-extent of radiation associated with fluoroscopy and x-ray examination of the intestinal tract.^[1]

External links

• KINEVAC (sincalide) on NIH.gov

References